Long Non-Coding RNA BACE1-AS Modulates Isoflurane-Induced Neurotoxicity to Alzheimer’s Disease Through Sponging miR-214-3p

He, Wei; Chi, Songyuan; Jin, Xing; Lu, Jiuwei; Zheng, Wei; Yan, Jie; Zhang, Duo

doi:10.1007/s11064-020-03091-2

Cited by 29 publications

(25 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mice were used as the model in 36 animal studies, and zebrafish was used in one study. There are 16 different cell lines used in these studies, including SH-SY5Y in 16 studies (Massone et al, 2011 ; Vaure and Liu, 2014 ; Huang et al, 2017 , 2020 ; Cai et al, 2018 ; Li H. et al, 2018 ; Ke et al, 2019 ; Ma et al, 2019 ; Wang X. et al, 2019 ; Zeng et al, 2019 ; Zhang M. et al, 2019 ; Chen et al, 2020 ; Qasim et al, 2020 ; Wang Q. et al, 2020 ; Xu et al, 2020 ; Yan et al, 2020 ; Zhao et al, 2020 ; Zhou Y. et al, 2020 ; Zhang and Wang, 2021 ), HEK293 in 12 studies (Faghihi et al, 2008 ; Cai et al, 2017 ; Ghanbari et al, 2019 ; Ke et al, 2019 ; Zeng et al, 2019 ; Zhang et al, 2019 ; Zhu et al, 2019 ; Ge et al, 2020 ; Huang et al, 2020 ; Zhou B. et al, 2020 ; Zhang and Wang, 2021 ), PC12 in seven studies (Guo et al, 2018 ; Wang J. et al, 2018 ; Ma et al, 2019 ; Zhao et al, 2019 ; Bastard et al, 2020 ; Zhou B. et al, 2020 ; Zhang et al, 2021 ), SK-N-SH in 5 studies (Ke et al, 2019 ; Gao et al, 2020 ; Ge et al, 2020 ; He et al, 2020 ; Xu et al, 2020 ), N2A in five studies (Cai et al, 2017 ; Li D. et al, 2018 ; Butler et al, 2019 ; Huang et al, 2020 ; Yue et al, 2020 ), U251 in two studies (Lin et al, 2019 ; Zeng et al, 2019 ), Human peripheral neurons (HPNs) in two studies (Zeng et al, 2019 ; Ge et al, 2020 ), SK-N-F1 (Kang et al, 2014 ), RAW264.7 (Yamanaka et al, 2015 ), Hela (Spreafico et al, 2018 ), CHP212 (Gao et al, 2020 ...…”

Section: Resultsmentioning

confidence: 99%

“…Due to the large volume of methods and tests performed in these studies, only the major methods are mentioned. The distribution of studies is limited to only seven countries, in which China with 54 studies has a significant share (Vaure and Liu, 2014 ; Luo et al, 2015 ; Zhang et al, 2016 , 2021 ; Cai et al, 2017 , 2018 ; Deng et al, 2017 ; Fang et al, 2017 ; Huang et al, 2017 , 2020 ; Yang et al, 2017 ; Feng et al, 2018 ; Guo et al, 2018 ; Li D. et al, 2018 ; Li H. et al, 2018 ; Liu et al, 2018 ; Wang J. et al, 2018 ; Wang X. et al, 2018 , 2019 ; Zhang T. et al, 2018 ; Ke et al, 2019 ; Lin et al, 2019 ; Ma et al, 2019 , 2020 ; Tang et al, 2019 ; Yi et al, 2019 ; Zeng et al, 2019 ; Zhang M. et al, 2019 ; Zhu et al, 2019 ; Bastard et al, 2020 ; Chen et al, 2020 ; Gao et al, 2020 ; Ge et al, 2020 ; He et al, 2020 ; Hong et al, 2020 ; Li et al, 2020 ; Qasim et al, 2020 ; Wang D. et al, 2020 ; Wang Q. et al, 2020 ; Xu et al, 2020 ; Yan et al, 2020 ; Yue et al, 2020 ; Zhao et al, 2020 ; Zhou B. et al, 2020 ; Zhou Y. et al, 2020 ; Zhuang et al, 2020 ; Zhang and Wang, 2021 ), followed by the United States with five studies (Faghihi et al, 2008 ; Airavaara et al, 2011 ; Kang et al, 2014 ; Yamanaka et al, 2015 ; Butler et al, 2019 ), Iran (Azizi-Aghaali et al, 2018 ; Fotuhi et al, 2019 ; Azadfar et al, 2020 ), and Italy (Massone et al, 2011 ; Spreafico et al,…”

Section: Resultsmentioning

confidence: 99%

“…In the Plasma of AD patients and SK-N-SH and SK-N-AS cells treated with Aβ and isoflurane, the BACE1-AS was upregulated, while miR-214-3p was downregulated. Additionally, miR-214-3p improved cognitive status in mouse models by preventing autophagy and reducing apoptosis via suppressing Atg12 expression (He et al, 2020 ). Therefore, BACE1-AS can play a critical role in the monitoring and management of AD.…”

Section: The Perspective Of Up-regulated Lncrnas In Admentioning

confidence: 99%

See 2 more Smart Citations

The Perspective of Dysregulated LncRNAs in Alzheimer's Disease: A Systematic Scoping Review

Asadi

Hassani

Kiani

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

LncRNAs act as part of non-coding RNAs at high levels of complex and stimulatory configurations in basic molecular mechanisms. Their extensive regulatory activity in the CNS continues on a small scale, from the functions of synapses to large-scale neurodevelopment and cognitive functions, aging, and can be seen in both health and disease situations. One of the vast consequences of the pathological role of dysregulated lncRNAs in the CNS due to their role in a network of regulatory pathways can be manifested in Alzheimer's as a neurodegenerative disease. The disease is characterized by two main hallmarks: amyloid plaques due to the accumulation of β-amyloid components and neurofibrillary tangles (NFT) resulting from the accumulation of phosphorylated tau. Numerous studies in humans, animal models, and various cell lines have revealed the role of lncRNAs in the pathogenesis of Alzheimer's disease. This scoping review was performed with a six-step strategy and based on the Prisma guideline by systematically searching the publications of seven databases. Out of 1,591 records, 69 articles were utterly aligned with the specified inclusion criteria and were summarized in the relevant table. Most of the studies were devoted to BACE1-AS, NEAT1, MALAT1, and SNHG1 lncRNAs, respectively, and about one-third of the studies investigated a unique lncRNA. About 56% of the studies reported up-regulation, and 7% reported down-regulation of lncRNAs expressions. Overall, this study was conducted to investigate the association between lncRNAs and Alzheimer's disease to make a reputable source for further studies and find more molecular therapeutic goals for this disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: The Perspective Of Up-regulated Lncrnas In Admentioning

confidence: 99%

See 1 more Smart Citation

The Perspective of Dysregulated LncRNAs in Alzheimer's Disease: A Systematic Scoping Review

Asadi

Hassani

Kiani

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…Additionally, BACE1-AS acts as a sponge for miR-214-3p, and miR-214-3p silencing reverses the effects of BACE1-AS knockdown on isoflurane-mediated apoptosis in Aβ-induced SK-N-SH cells. These data suggest that BACE1-AS aggravates isoflurane-induced neurotoxicity in AD via miR-214-3p sponging (He et al, 2020 ).…”

Section: Ndd-related Lncrnasmentioning

confidence: 95%

Long Noncoding RNAs in Neurodegenerative Diseases: Pathogenesis and Potential Implications as Clinical Biomarkers

Zhang

Bian

2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Neurodegenerative diseases (NDDs), including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), are progressive and ultimately fatal. NDD onset is influenced by several factors including heredity and environmental cues. Long noncoding RNAs (lncRNAs) are a class of noncoding RNA molecules with: (i) lengths greater than 200 nucleotides, (ii) diverse biological functions, and (iii) highly conserved structures. They directly interact with molecules such as proteins and microRNAs and subsequently regulate the expression of their targets at the genetic, transcriptional, and post-transcriptional levels. Emerging studies indicate the important roles of lncRNAs in the progression of neurological diseases including NDDs. Additionally, improvements in detection technologies have enabled quantitative lncRNA detection and application to circulating fluids in clinical settings. Here, we review current research on lncRNAs in animal models and patients with NDDs. We also discuss the potential applicability of circulating lncRNAs as biomarkers in NDD diagnostics and prognostics. In the future, a better understanding of the roles of lncRNAs in NDDs will be essential to exploit these new therapeutic targets and improve noninvasive diagnostic methods for diseases.

show abstract

“…Since then, lncRNAs have been found to be dysregulated in brain tissues of AD mouse models compared to healthy and age-matched controls and demonstrate differential expression within disease models in an age-dependent manner [67,68]. Attempts to characterize lncRNAs involved in disease neuropathology have repeatedly described the involvement of lncRNA BACE1 in AD [69,70]. BACE1 is a crucial regulator in amyloid beta production, a ratelimiting step in AD progression [51].…”

Section: Trnasmentioning

confidence: 99%

Nucleic Acid Liquid Biopsies in Alzheimer’s Disease: Current State, Challenges, and Opportunities

Soelter¹,

Whitlock²,

Williams³

et al. 2021

Preprint

View full text Add to dashboard Cite

Alzheimer’s disease is the most common neurodegenerative disease and affects persons of all races, ethnic groups, and sexes. The disease is characterized by neuronal loss leading to cognitive decline and memory loss. There is no cure and the effectiveness of existing treatments is limited and depends on the time of diagnosis. The long prodromal period, during which patients’ ability to live a normal life is not affected despite neuronal loss, often leads to a delayed diagnosis because it can be mistaken for normal aging of the brain. In order to make a substantial impact on AD patients, early diagnosis may provide a greater therapeutic window for future therapies to slow AD-associated neurodegeneration. Current gold standards for disease detection include magnetic resonance imaging and positron emission tomography scans, which visualize amyloid β and phosphorylated tau depositions and aggregates. Liquid biopsies, already an active field of research in precision oncology, are hypothesized to provide early disease detection through minimally or non-invasive sample collection techniques. Liquid biopsies in Alzheimer’s disease have been studied in cerebrospinal fluid, blood, ocular, oral, and olfactory fluids. However, most of the focus has been on blood and cerebrospinal fluid due to biomarker specificity and sensitivity attributed to the effects of the blood-brain barrier and inter-laboratory variation during sample collection. Many studies have identified amyloid β and phosphorylated tau levels as putative biomarkers, however, advances in next-generation sequencing-based liquid biopsy methods have led to significant interest in identifying nucleic acids species associated with Alzheimer’s disease from liquid tissues. Differences in cell-free RNAs and DNAs have been described as potential biomarkers for AD and hold the potential to affect disease diagnosis, treatment, and future research avenues.

show abstract

Long Non-Coding RNA BACE1-AS Modulates Isoflurane-Induced Neurotoxicity to Alzheimer’s Disease Through Sponging miR-214-3p

Cited by 29 publications

References 32 publications

The Perspective of Dysregulated LncRNAs in Alzheimer's Disease: A Systematic Scoping Review

The Perspective of Dysregulated LncRNAs in Alzheimer's Disease: A Systematic Scoping Review

Long Noncoding RNAs in Neurodegenerative Diseases: Pathogenesis and Potential Implications as Clinical Biomarkers

Nucleic Acid Liquid Biopsies in Alzheimer’s Disease: Current State, Challenges, and Opportunities

Contact Info

Product

Resources

About